The designer’s collection at Milan Fashion Week Spring 2025 celebrated both childlike insouciance and the concept of oneness

The biotech will first tackle lysosomal storage disorders

CAR T-cell therapy works wonders for some cancer patients. For others, it is a death sentence. To make the revolutionary therapy work for more people, scientists must devise better ways to control it

The drug company will pay $1.6 billion to gain Armo’s IL-10 program

Joined by CRISPR luminaries Feng Zhang and J. Keith Joung, the Harvard chemist raises up to $87 million in funding

The start-up, based on the work of Broad Institute scientist Aviv Regev, has raised $65 million to develop therapies for cancer and autoimmune disease

With $40 million series A funding, the start-up will develop inhibitors of proteins that make chemical modifications to RNA

Joined by CRISPR luminaries Feng Zhang and J. Keith Joung, the Harvard chemist raises up to $87 million in funding

A new report from the Cancer Research Institute highlights the U.S. and China as cell therapy leaders

With so many ingredients on hand, can the oncology community figure out how to sensibly and efficiently combine checkpoint inhibitors with other drugs?

The startup is developing allosteric activators to increase levels of the vital metabolic molecule coenzyme A in pantothenate kinase-associated neurodegeneration

The early peek at data from a Phase I/II study excited families, physicians, and investors 

Piramal sites on different continents have become involved in producing Theracos’s diabetes treatment

The drug company is partnering with Calibr to develop universal CAR T-cells directed to different tumors via antibody switches

Skyhawk will receive $60 million up front to develop drug candidates that target RNA in neurological diseases

The drug company is partnering with Calibr to develop universal CAR T cells directed to different tumors via antibody switches

Researchers are working to fix genetic conditions like Gaucher disease before birth by testing experimental therapies on fetal animals

The company claims its technology will allow it to access previously undruggable targets

The company claims its technology will allow it to access previously undruggable targets

After winning the “MTV Roadies X4”, Balraj Singh Khera emphasises the need to drive away the fear of failure

A corona warrior who got infected on the line of duty almost defeated Covid-19 after battling for two weeks but lost to kidney infection.

Mother’s Day heartache for son of slain mum  Herald SunView Full coverage on Google News

Two Princeton University studies are opening important new windows into understanding an untreatable group of common genetic disorders known as RASopathies that affect approximately one child out of 1,000 and are characterized by distinct facial features, developmental delays, cognitive impairment and heart problems. The findings could help point the way toward personalized precision therapies for these conditions.

Antibodies are widely used as cancer therapeutics, but their current use is limited by the low number of antigens restricted to cancer cells. A receptor tyrosine kinase, receptor tyrosine kinase-like orphan receptor 2 (ROR2), is normally expressed only during embryogenesis and is tightly down-regulated in postnatal healthy tissues. However, it is up-regulated in a diverse set of hematologic and solid malignancies, thus ROR2 represents a candidate antigen for antibody-based cancer therapy. Here we describe the affinity maturation and humanization of a rabbit mAb that binds human and mouse ROR2 but not human ROR1 or other human cell-surface antigens. Co-crystallization of the parental rabbit mAb in complex with the human ROR2 kringle domain (hROR2-Kr) guided affinity maturation by heavy-chain complementarity-determining region 3 (HCDR3)-focused mutagenesis and selection. The affinity-matured rabbit mAb was then humanized by complementarity-determining region (CDR) grafting and framework fine tuning and again co-crystallized with hROR2-Kr. We show that the affinity-matured and humanized mAb retains strong affinity and specificity to ROR2 and, following conversion to a T cell–engaging bispecific antibody, has potent cytotoxicity toward ROR2-expressing cells. We anticipate that this humanized affinity-matured mAb will find application for antibody-based cancer therapy of ROR2-expressing neoplasms.

Producer Karim Morani's daughter Zoa Morani donated her blood for plasmatherapy trials for COVID-19 treatment at Mumbai's Nair hospital today.

For the past few weeks, Windsor's new pandemic response therapist Dana St. Jean has been spending her time fielding phone calls and speaking with people over video chat to find ways to help them cope with the stresses of COVID-19.

One size fits all? How wrong you are

Source: www.washingtontimes.com - Sunday, May 10, 2020
OAKLAND PARK, Fla. (AP) - There is nothing like a big smooch, gentle touch or a wet nose nuzzle with a happy dog. But social distancing rules, due to the impact of COVID-19, has created a barrier between those in need of canine therapy visits and those special pups that ...

NOWSHERA: The confirmed Covid-19 cases reached to 110 after two more test positive for the viral infection in the district on Saturday. DC Nowshera Shahid Ali Khan that two suspected patients of coronavirus identified as wife of Akmal Shah, resident of Amangarh, and Sabz Ali of Pabbi tested...